Navigation Links
New tumor markers determine therapy intensity
Date:3/17/2009

tumor after surgery, and existence of metastases at diagnosis.

Patients with a poor prognosis can be treated more intensively

Stefan Pfister and his research group "Molecular Genetics of Pediatric Brain Tumors" first described the new tumor markers in the medulloblastoma in 2007. For the current study, he examined tumor samples from 340 patients and compared the documented course of disease with genetic aberrations in the tumor DNA. Aberrations were seen at the chromosome level, the units in which the entire genetic information is distributed and contained. Each chromosome contains large amounts of genetic information; the entire genetic material of humans is distributed in 23 such portions, each of which is usually present in two copies (2 x 23 chromosomes). Stefan Pfister discovered that if entire segments of chromosomes number 6 and 17 are present in three copies (instead of the usual 2 copies) in the genetic material of the brain tumors, the patient's prognosis is poor. If however, one copy of chromosome 6 is missing in the tumor, the patients in the collective observed always survived. The combination of these and other characteristics led to a classification of the patients in a total of five groups requiring varying levels of intensity in treatment.

"With these markers, we can reliably identify patients with a poor prognosis and treat them more intensely from the start," said Dr. Stefan Pfister. "At the same time, we can reduce the treatment intensity for patients who will presumably respond especially well to radiation and chemotherapy. We can thus reduce consequential damage and the risk of secondary malignancies."

Another advantage of the new markers the test is very robust and can be carried out within 48 hours in any neuropathology laboratory on tissue samples conventionally preserved in paraffin.

BMBF promotes the search for other tumor markers

The prospective validation of these mar
'/>"/>

Contact: Dr. Stefan Pfister
s.pfister@dkfz.de
062-215-64555
University Hospital Heidelberg
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
2. Tiny tool to control growing blood vessels opens new potential in tumor research
3. Researchers isolate protein domain linked to tumor progression
4. Singapore research organisations team up to advance drug discovery using brain tumor stem cells
5. Scattered light rapidly detects tumor response to chemotherapy
6. New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome
7. Stress may hasten the growth of melanoma tumors
8. Implants mimic infection to rally immune system against tumors
9. UC Davis researchers find molecule that targets brain tumors
10. Researchers identify new anti-tumor gene
11. Novel technique for fluorescence tomography of tumors in living animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... for months after a traumatic brain injury (TBI), revealing ... new research led by the University of Melbourne, Australia ... Neurotrauma Initiative is published in the latest issue of ... Around 400,000 Australians have a disability related to traumatic ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... results on Wednesday, November 10, 2010 after the markets close. PDL,s ... Eastern Time to discuss the financial results.   ... call via phone, please dial (866) 271-5140 from the United States ...
... HAGUE (2 November 2010)A unique acacia known as a "fertilizer ... maize yields in smallholder agriculture in Zambia and Malawi, according ... The findings were central to the arguments of agroforestry experts ... technology more widely throughout the African nations most vulnerable to ...
Cached Biology News:Study provides treatment hope for long term effects of brain trauma 2PDL BioPharma to Announce Third Quarter 2010 Financial Results on November 10, 2010 2Scientists find that evergreen agriculture boosts crop yields 2Scientists find that evergreen agriculture boosts crop yields 3
(Date:3/3/2015)... 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life ... and products for advanced microarray diagnostics, today announced ...  to its Management team. In his capacity as ... transition from a development stage to a commercially ... the Company,s capital market strategy and to secure ...
(Date:3/3/2015)... LITTLE FALLS, N.J. , March 3, 2015 /PRNewswire/ ... a biotechnology company specializing in the development of and ... of damaged tissues and organs, announced today that it ... Purchase Agreement with Amarantus Bioscience Holdings, Inc. (OTC Bulletin ... required under the Agreement, Amarantus made the final payments ...
(Date:3/3/2015)... 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... journal, Expert Opinion on Biological Therapy , Dr. ... Zhenggang Zhang , at the Henry Ford Hospital in ... beta 4 (TB4) has the capacity to promote CNS ... more post-injury, leading to neurological recovery in each case.  ...
(Date:3/3/2015)... 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... the lives of pets, announced today that it will release ... 12, 2015 after the market close. The Company will host ... Interested parties may access the call by ... internationally, and using conference ID 98449349.  The ...
Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... May 26 , - Production Increase Brings ... Therapeutics (Euronext: AMT), a leader in the field,of ... a Cooperative,Research and Development Agreement from the National ... Institutes of Health (NIH), Bethesda,Maryland, that promises to ...
... AMLN ) will Web cast its Annual Meeting ... PT from the company,s corporate,headquarters in San Diego, CA. ... Executive Officer of Amylin Pharmaceuticals,will be providing a corporate ... and a recording will be made,available following the event. ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... Patent 2,360,833 entitled "Reovirus for the Treatment ... use of one or more,recombinant reoviruses to ... provides the Company with additional patent protection ...
Cached Biology Technology:AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 2AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity 3Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent 2
HES-1 [Hairy 1], Available Summer 2003...
E1A (adenovirus early region 1)...
... 1 ( Abpromise for all tested ... peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK EDILYHFNLT TSRHNFPALF GDVKFVCVGG ... acids 1-99 of Human Uridine Phosphorylase 1 ... 7378 Swiss Protein ID: ...
Nucleobindin 1 [NUCB1]...
Biology Products: